This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Umit Özyurda A. Ruchan Akar Mehmet Ozkan Alp Aslan Refik Tasoz Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Özyurda, U. Articles by Tasoz, R. Search for Related Content PubMed PubMed Citation Articles by Özyurda, U. Articles by Tasoz, R. Related Collections Cardiac - other Valve disease

Early clinical experience with the On-X prosthetic heart valve

Umit Özyurda^a, A. Ruchan Akar^a,*, Ozge Uymaz^a, Mehmet Oguz^b, Mehmet Ozkan^b, Celil Yldrm^b, Alp Aslan^b and Refik Tasoz^a

^a Department of Cardiovascular Surgery, Heart Center, University of Ankara School of Medicine, Dikimevi, Ankara, Turkey
^b Division of Cardiovascular Surgery, Private Yaam Hospital, Ankara, Turkey

*Corresponding author. Tel.: +90 312 3623030/6054; fax: +90 312 3625639. Website: http://www.medicine.ankara.edu.tr/cerrahitip/kvc/.

E-mail address: rakar{at}medicine.ankara.edu.tr. (A.R. Akar).

The study aimed to assess the performance of the On-X valve (Medical Carbon Research Institute, Austin, TX). Between December 2000 and January 2003 On-X valves were implanted in 400 patients aged 19–85 years (mean: 55.6±16), 290 males and 210 females. There were 120 cases of aortic valve replacement (AVR), 258 mitral valve replacement (MVR) and 22 combined aortic and mitral valve replacement (DVR). Additional procedures were performed in 144 patients. Patients were followed up prospectively at 3- to 6-month intervals. Mean follow-up was 38.4±11.8 months (maximum 55.6 months). Overall hospital mortality was 3.5%. Freedom from adverse events at 4 years in the study were as follows: thromboembolism, 99.1% for AVR, 98.3% for MVR and 94.7% for DVR patients; thrombosis, 100% for AVR, 99.2% for MVR and 94.7% for DVR; bleeding events, 99.1% for AVR, 99.2% for MVR and 88.8% for DVR; prosthetic endocarditis, 98.2% for AVR, 99.2% for MVR and 94.7% for DVR. Overall survival at 4 years was 92±1%. At echocardiographical examination within 1 year of the AVR, the mean aortic valve gradient was 12.8±6, 10.3±3, 9.0±4, 8.3±3, and 6.2±3 mmHg for 19, 21, 23, 25, 27/29 mm valve sizes, respectively. MVR mean gradient was 4.9±2, 4.5±1.2 and 4.0±0.8 mmHg for 25, 27/29, 31/33 mm valve sizes, respectively. On-X valve is a highly effective mechanical valve substitute with low morbidity and mortality and good functional results.

Key Words: Valve surgery; Bileaflet mechanical valve; On-X valve; Late results